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Abstract
Cdc7 is a conserved serine/threonine kinase essential for the initiation of DNA replication, likely by activating the
MCM DNA helicase at the G1- to S-phase transition. Cdc7 kinase activity requires association with its regulatory
subunit Dbf4/activator of S-phase kinase. Cdc7-Dbf4 is also downstream of the conserved Ataxia telangectasia and
RAD3-related kinase that responds to stalled replication forks or DNA damage. In this study, we found that Cdc7
protein was very low or undetectable in normal tissues and cell lines but had increased expression in ∼50% of the
62 human tumor cell lines we examined. Most cell lines with increased Cdc7 protein levels also had increased
Dbf4 abundance, and some tumor cell lines had extra copies of the DBF4 gene. A high expression of Cdc7 protein
was also detected in primary breast, colon, and lung tumors but not in the matched normal tissues. We also found
a high correlation between p53 loss and increased CDC7 and DBF4 expression in primary breast cancers (P = 3.6 ×
10−9 and 1.8 × 10−10, respectively) and in the cancer cell lines we studied. Therefore, increased Cdc7-Dbf4 abun-
dance may be a common occurrence in human malignancies.
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Introduction
The initiation of DNA synthesis requires the assembly of a multi-
protein complex at replication origins during G1-phase [1]. These
“licensed” replication complexes are activated to initiate DNA syn-
thesis by cyclin-dependent kinases and by the Cdc7-Dbf4 kinase
[2]. Cdc7 kinase activity requires a regulatory subunit called Dbf4,
which is cyclically expressed during the cell cycle and peaks during
S-phase [3,4]. Although first identified in the budding yeast [5,6],
orthologs of CDC7 and DBF4 have been found in fission yeast,
Aspergillus, Drosophila, Xenopus, mice, and humans, where DBF4
is also called the activator of S-phase kinase (ASK) [7–12]. Here,
we will refer to this subunit as Dbf4. In Xenopus and human cells,
another Dbf4-related protein (Drf1) can bind to and activate Cdc7
kinase [4,13]. Drf1 is most active during the early embryonic cycles
in Xenopus and is absent after gastrulation, suggesting that it may be
developmentally regulated in other vertebrate organisms as well [14].
In all organisms, Cdc7 kinase is essential for the initiation of DNA
replication likely through its ability to phosphorylate key replication
proteins [1]. Recently, it was reported that Cdc7-Dbf4 phosphoryla-
tion of Mcm2 is essential for the initiation of DNA replication in
mammalian cells [15,16].
The Cdc7-Dbf4 protein kinase is a target of the S-phase check-
point pathway, and it has an important role in promoting a proper
response to DNA damage in multiple organisms [7,17]. Vertebrate
Cdc7-Dbf4 is downstream of the Ataxia telangectasia and RAD3-
related (ATR) and Chk1 checkpoint kinases in response to UV irra-
diation [18] where its activity may be inhibited to prevent initiation
events. Cdc7 is also a downstream target of ATR and Chk2 after repli-
cation fork stalling [19,20], although it is not known if Cdc7 or Dbf4
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are direct targets of ATR or Chk1/2. Cdc7-Dbf4 is therefore an es-
sential cell cycle regulator that is also important for genome integrity
in the response to DNA damage or replication fork arrest.
Previous studies examining proteins required for the initiation of
DNA replication have shown that Cdc6, Mcm2, Mcm5, and Cdt1
are variously up-regulated in cancers of the bladder, colon, cervix,
and lung [21–28]. CDC7 mRNA expression is also altered in some
cancer cell lines and primary tumors [29], and furthermore, somatic
CDC7 mutations were identified in colorectal and gastric carcinomas
through comprehensive kinome screens of human tumors [30,31].
These data suggest that alterations in Cdc7-Dbf4 protein abundance
or activity may occur during tumorigenesis and have important con-
sequences for cell survival. Indeed, Nambiar et al. [32] characterized
Dbf4 as a novel determinant in cutaneous melanoma development
with prognostic relevance. They showed that Dbf4 protein is in-
creased in primary melanoma, melanoma metastasis, and melanoma
cell lines.
In this study, we compared levels of Cdc7 protein expression in the
NCI-60 and additional leukemia cell lines to normal cell lines and tis-
sues. About 50% of 62 tumor cell lines we examined had increased
Cdc7 protein abundance. Furthermore, Cdc7-Dbf4 expression levels
were correlated in these cancer cell lines. Immunohistochemical anal-
ysis of primary tumors showed moderate to intense Cdc7 staining in
some breast, colon, and lung cancers but no staining in matched nor-
mal tissue. Interestingly, although Cdc7-Dbf4 expression was high in
multiple cell lines and primary breast tumors with mutant p53, we
found no evidence that p53 expression or induction regulated CDC7
and DBF4 mRNA levels. To investigate whether increased CDC7 or
DBF4 copy number might contribute to Cdc7-Dbf4 protein overex-
pression, we examined the DBF4 and CDC7 genes by fluorescence
in situ hybridization (FISH). Although we did not detect CDC7
amplification, multiple copies of DBF4 were detected in 5 of 14
tumor cell lines examined and in 1 primary tumor. Knockdown of
Cdc7 expression in tumor cell lines caused growth arrest with or
without apoptosis as seen previously [33]. Together, our results indi-
cate that increased Cdc7-Dbf4 protein expression is a common oc-
currence in human malignancies and suggest that inactivation of the
p53 tumor suppressor or increased DBF4 copy number may be con-
tributing mechanisms.
Materials and Methods
Cell Lines
The normal human fetal lung fibroblasts WI-38, the normal human
lung fibroblasts IMR-90, and HeLa cells were maintained in mini-
mum essential medium with Earle’s salts supplemented with 10%
(vol/vol) heat-inactivated fetal bovine serum (HI FBS), 2 mM glu-
tamine, 1.5 g/L sodium bicarbonate, 0.1 nM nonessential amino
acids, 1 mM sodium pyruvate, and 50 U/ml and 50 μg/ml penicillin/
streptomycin, respectively. Tumor cell lines from the NCI-60 set were
maintained in RPMI-1640 medium (Invitrogen, Carlsbad, CA) sup-
plemented with 10% (vol/vol) HI FBS and 0.05 mg/ml gentamicin.
The leukemia cell lines from the NCI-60 set and the five additional
leukemia cell lines MOLT-3, Jurkat clone E6-1, A3, GDM-1, and
KG-1 were grown in suspension in RPMI-1640 medium supple-
mented with 10% (vol/vol) HI FBS and 0.05 mg/ml gentamicin.
The HCT-116 p53+/+ and p53−/− cell lines were a gift from B.
Vogelstein [34]. They were cultured in McCoy’s 5A medium supple-
mented with 10% (vol/vol) HI FBS.
The bone marrow mononuclear cells were issued from healthy
adults and obtained from Cambrex (Walkersville, MD). They were
cultured in Iscove’s modified Dulbecco’s medium, which is a modi-
fied Dulbecco’s modified Eagle’s medium containing high glucose
(4500 mg/L), sodium pyruvate, additional amino acids, and HEPES
and is supplemented with 15% (vol/vol) HI FBS, 200 nM gluta-
mine, and 2 ng/ml stem cell factor.
Antibodies
Monoclonal antibodies were separately raised against purified
GST-HsCdc7 and recombinant HsCdc7-Dbf4 kinase. Antibodies
were screened for their ability to immunoblot recombinant HsCdc7
or HsDbf4. We identified multiple monoclonal cell lines that pro-
duce anti-Cdc7 and anti-Dbf4 antibodies with a variety of properties,
four of which were used in this study: Cdc7-4D9, Cdc7-10B9,
Cdc7-2G1, and Dbf4-8H6.
Monoclonal antibodies against the human β-actin and poly(ADP)-
ribose polymerase (PARP) proteins were purchased from Sigma (St.
Louis, MO) and Cell Signaling Technology (Danvers, MA), respec-
tively. Horseradish peroxidase–conjugated secondary antibodies were
obtained from Amersham Biosciences (Piscataway, NJ).
Immunoblot Analysis
Whole-cell extracts were prepared by resuspending cell pellets in
RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycho-
late, 0.1% SDS, and 50 mM Tris [pH 8]). The concentrations of
proteins in the extracts were determined using the BCA Protein
Assay Reagent Kit (Pierce, Rockford, IL) according to the manufac-
turer’s protocol. Equal amounts of proteins were separated in 10%
SDS-PAGE gel and were transferred to a nitrocellulose membrane
(Millipore Inc., Billerica, MA). Membrane was stained with Ponceau
S dye to check for equal loading and homogeneous transfer. The pro-
teins were visualized using the SuperSignal West Pico Chemilumines-
cent Substrate kit from Pierce.
Fluorescence In Situ Hybridization
DNA probes recognizing the DBF4 and CDC7 genes are derived
from BAC clones RP11-104E6 (location 7q21.12) and RP11-47K11
(location 1p22.2), respectively. They were purchased from BACPAC
Resources, Children’s Hospital Oakland Research Institute, Oakland,
CA. Fluorescence in situ hybridization probes were generated using
Vysis SpectrumOrange-conjugated dUTP and the Vysis Nick trans-
lation labeling kit following manufacturer’s protocol (Abbott Molec-
ular Inc., Des Plaines, IL). On chromosome 1, we used a control
probe at the location 1q21.1 (RP11-337C18) labeled with Vysis
SpectrumGreen-conjugated dUTP. For the chromosome 7, we used
a commercial centromeric probe CEP7 SpectrumGreen (α satellite)
that hybridizes to the centromere (band region 7p11.1–q11.1, locus
D7Z1; Abbott Molecular Inc.). Fluorescence in situ hybridization ex-
periments were done on cell lines, on metaphase preparations, and
frozen tissue sections following standard protocols. Metaphases were
prepared following a standard cytogenetic technique. Slides were
mounted with VECTASHIELD Mounting Medium with DAPI
(VECTOR Laboratories, Burlingame, CA). Fluorescence in situ hy-
bridization control experiments were done on Vysis Normal Male
Metaphase Comparative Genomic Hybridization Target Slides made
from phytohemagglutinin-stimulated lymphocytes derived from a
karyotypically normal male donor (Abbott Molecular Inc.).
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Fifty nuclei were analyzed per cell line or per tissue section.
Counting was performed, and calculation of ratios was done by di-
viding 7q21.12 (DBF4) by CEP7 signals and dividing 1p22.2
(CDC7) by 1q21.1 (control) signals in interphase FISH experiments.
Ratios that were ≥1.5 were considered overrepresented, and ratios ≥
2.5 were considered as amplified. Counting was performed with a
fluorescence microscope (Axioplan 2 Imaging; Zeiss, Thornwood,
NY). The pictures were taken at an original magnification of ×63
with a fluorescence microscope (Model BX51; Olympus, Center
Valley, PA) using the software Case Data Manager (Version 5.0).
Tissue Samples
Whole human normal tissue homogenates from brain, kidney, liver,
lung, mammary gland, ovary, prostate, and small intestine were de-
rived from healthy humans who died of trauma or sudden death
(Protein Medley; BD Biosciences Clontech, Palo Alto, CA). Patients
who had surgery for invasive beast, lung, and colon cancers were
identified through searching the histopathology records available at
the Van Andel Research Institute (Grand Rapids, MI). Sections were
cut from fresh frozen breast, lung, and colon primary tumors issued
from 35 different patients according to standard protocols. For six
patients, the matched normal tissues were available. Sections were
preserved at −80°C until use.
Immunohistochemistry
Frozen sections were fixed in 70% ethanol for 10 minutes. Im-
munohistochemistry was performed with the Vectastain ABC Kit
(VECTOR Laboratories) according to the manufacturer’s protocol.
Endogenous peroxidase activity was first blocked by a 30-minute in-
cubation of the sections in 0.03% hydrogen peroxide. After incuba-
tions with primary and secondary antibodies, sections were incubated
in peroxidase substrate solution until the desired staining intensity
developed. We used the diaminobenzidine (DAB) Substrate Kit for
Peroxidase (VECTOR Laboratories). Then, the sections were washed
for 5 minutes in water. They were counterstained in hematoxylin
(VECTOR Laboratories) and were mounted in Cytoseal60 (Richard-
Allan Scientific, Kalamazoo, MI). Sections were analyzed using a
bright microscope (ECLIPSE E600; Nikon, Melville, NY), and pic-
tures were taken at the original magnifications of ×20 and ×40 with
the SPOT software (Version 4.0.4; Diagnostic Instruments Inc.,
Sterling Heights, MI).
Gene Expression Analysis
To examine the relationship between CDC7 expression, DBF4 ex-
pression, and TP53 gene status, preprocessed gene expression data
were obtained from the Gene Expression Omnibus (GSE3494,
GSE4922) [35–37]. Expression values for CDC7 and DBF4 were
isolated, and expression differences between wild type and mutated
TP53 tumors were evaluated using a two-sided Student’s t test. For
the expression analysis in additional tumors, unprocessed gene ex-
pression data derived from more than 1000 tumors were obtained
from Gene Expression Omnibus (GSE2109). Gene expression values
were preprocessed using the RMA method as implemented in the
BioConductor affy package for the R environment [38,39] using up-
dated probe set mappings [40]. For each tumor gene expression value,
the median gene expression value of the corresponding nondiseased
tissue was subtracted. Tumor samples that could not be associated with
the corresponding nondiseased tissue were not evaluated. Relative gene
expression levels for CDC7 and DBF4 could be established in 678 tu-
mor samples (breast = 181, cervix = 13, colon = 134, endometrium =
58, kidney = 91, lung = 53, lymph = 6, ovary = 102, pancreas = 5,
prostate = 19, stomach = 6, and thyroid = 10). DBF4 expression was
evaluated with respect to CDC7 expression and tumor subtype using
linear regression. From the regression model, an adjusted R2 and a sig-
nificance value were computed.
The association between CDC7 protein expression and p53 mu-
tant status in the NCI-60 cell lines was determined using binomial
logistic regression where “−” or “+” represented “low” expression and
“++”, “+++,” or “++++” represented “high” expression. The model
was fit to a combined data set, and to adjust for measurement differ-
ences, a term for experimenter was included.
RNA Interference
All siRNA were from Dharmacon (Lafayette, CO). The sequence of
the siRNA against CDC7 is AGU AGG ACC UGA AGA GAA A. A
“smart pool” against CDC7 gave similar knockdown and induced
apoptosis in HeLa cells, but a control nontarget siRNA (AUG AAC
GUG AAU UGC UCA A) had no effect on Cdc7 expression. All tu-
mor cell lines were transfected in six-well plates using 100 nM Cdc7
siRNA (or nontarget RNA) with Oligofectamine (Invitrogen, Carlsbad,
CA). Subsequent titrations with HeLa cells showed that we could de-
crease the siRNA concentration to 10 nM with similar results.
Cell viability was determined by Trypan blue staining (0.4%) using
standard methods, and terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) assays were performed according to the
manufacturer’s instructions (Roche, Indianapolis, IN).
Results
Cdc7-Dbf4 Protein Has Low Abundance in Normal Cell Lines
and Tissues But Is Highly Expressed in Many Cancer Cell Lines
We raised monoclonal antibodies against human Cdc7-Dbf4 ki-
nase and screened normal cells, the NCI-60 tumor cell lines plus five
additional leukemia cell lines for Cdc7 and Dbf4 protein abundance.
(We did not have access to the NCI-60 cell lines RXF-393, LOX
IMVI, and MDA-N.) We were unable to detect Cdc7 protein in nor-
mal tissues of different origins relative to β-actin (Figure 1A). We also
investigated the expression of the Cdc7 protein in whole-cell extracts
from normal human fetal lung fibroblasts (WI-38), normal human
lung fibroblasts (IMR-90 Figure 1B), and from bone marrow mono-
nuclear cells (data not shown) and only detected a signal for Cdc7
protein in the IMR-90 cells. Because we can detect subnanogram
amounts of recombinant Cdc7-Dbf4 proteins using our monoclonal
antibodies, these data suggest that Cdc7-Dbf4 protein levels are quite
low in normal cell lines and perhaps absent in postmitotic cells.
In contrast, the Cdc7 protein was overexpressed in ∼50% of 62
tumor cell lines relative to β-actin, which has a relatively constant
abundance between the different cell lines (Figure 1, C–K ). The leu-
kemia cell lines showed a wide range of Cdc7 protein expression
(Figure 1F ). K-562 (chronic myelogenous leukemia), MOLT-3
(acute lymphocytic leukemia), A3 and Jurkat E6-1 (two Jurkat, acute
T-cell leukemia), and MOLT-4 (acute lymphocytic leukemia) exhib-
ited a two- to fivefold increase of Cdc7 protein expression relative to
the leukemia lines with lower Cdc7 expression. The higher Cdc7 ex-
pression of these cells lines did not correlate with a faster growth rate.
Similarly, different levels of Cdc7 protein expression were observed
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for the central nervous system, colon, lung, melanoma, kidney, ovary,
prostate, and breast cancer cell lines (Figure 1). Cdc7 protein was also
very abundant in the two prostate cancer cell lines, namely, DU-145
and PC-3 (Figure 1J ). We also confirmed that CDC7 and DBF4
mRNA expression was induced in various leukemia cell lines as re-
ported previously [29] (data not shown).
In most cases, Dbf4 protein expression paralleled Cdc7 expression.
When Cdc7 protein was overexpressed, Dbf4 protein was either over-
expressed or present. When Cdc7 protein expression was very low
or absent, Dbf4 protein was also expressed at very low levels. The ex-
ceptions were two ovarian cancer cell lines OVCAR-4 and SK-OV-3
that had low levels of Cdc7 but significant Dbf4 expression. We
note that the NCI/ADR-RES cell line was originally thought to
be an adriamycin-resistant derivative of MCF7 but was recently de-
termined to derive from OVCAR-8 (human ovarian carcinoma cells)
[41]. Consistently, we saw that Cdc7 and Dbf4 were overexpressed in
both OVCAR-8 and NCI/ADR-RES (Figure 1, I and K ).
High Level of Cdc7-Dbf4 Expression Is Correlated with
p53 Loss
In Table 1, we list the doubling time, ploidy [42], relative Cdc7
protein levels (Figure 1), and the TP53 gene status [43] for the 57
cell lines from the NCI-60 set of tumor cell lines. Cdc7 protein was
scored as undetectable (−), weakly expressed (+), or overexpressed (++
to ++++) from two independent experiments (the second measure-
ments are summarized in Table W1). We found a significant asso-
ciation between Cdc7 protein expression and p53 mutational status
(P = .000324). Approximately 90% of the cells overexpressing Cdc7
in our two data sets were mutant for p53. However, there was no cor-
relation with Cdc7 (or Dbf4) protein expression and doubling time of
the cells (P = .271), indicating that Cdc7-Dbf4 expression is not cor-
related with growth rate.
To determine whether there is a correlation between TP53 status
and CDC7 or DBF4 mRNA expression in primary tumors, we ana-
lyzed the gene expression data from a breast cancer study in which
Figure 1. Abundance of Cdc7 and Dbf4 proteins in normal and tumor cell lines. Twenty micrograms of protein sample from whole-cell
extracts was separated on 10% SDS-PAGE gels for normal tissues of different origins (A), and immortalized IMR-90 and WI-38 fibroblast
cell lines (B). Panels (C–K) represent tumor cell lines of the central nervous system, colon, non–small cell lung, leukemia, melanoma,
kidney, ovary, prostate, and breast. After transfer, membranes were probed with a Cdc7- or Dbf4-specific antibody. Equal loading was
confirmed by probing with a β-actin–specific antibody. Asterisk (*) indicates the cell lines that were shown to be derived from the same
tumor [41,43].
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the TP53 gene status was determined using the Oncomine database
(www.ocomine.com). The study by Miller et al. [37] included Affy-
metrix data from 251 breast cancers, that is, 193 wild type and 58
mutant for TP53. By comparing the normalized CDC7 expression,
we found that CDC7 expression was significantly higher in breast
cancer with mutant TP53 (P = 3.6 × 10−9). Similarly, DBF4 expres-
sion was significantly higher in this data set for tumors with mutant
TP53 (P = 1.8 × 10−10). These data suggest that the increased CDC7
and DBF4 expression in breast tumors and in cancer cell lines from
diverse tissues can be related, at least in part, to the TP53 gene status.
A recent study suggested that several genes involved in DNA rep-
lication (including CDC7 and DBF4) may be repressed by p53 [44].
Therefore, we compared CDC7 and DBF4 mRNA expression using
reverse transcription–polymerase chain reaction (RT-PCR) in isogenic
HCT-116 p53+/+ and p53−/− cells [34]. The parental HCT-116 colon
tumor cells have a relatively normal diploid DNA content and have
intact DNA damage checkpoints. We found that CDC7 and DBF4
expression were indistinguishable in both cell lines (Figure W1A)
and we saw no difference in Cdc7-Dbf4 protein expression (data
not shown). To test whether the induction of p53 after exposure to
DNA damage repressed CDC7 and DBF4 expression, we also mea-
sured expression of these genes in HCT-116 p53+/+ cells after exposure
to bleomycin. Once again, we saw no evidence for p53 regulation of
CDC7 orDBF4 expression (Figure W1B) after exposure to DNA dam-
age. Thus, our data suggest that p53 does not directly regulate expres-
sion of the CDC7-DBF4 genes in HCT-116 cells.
DBF4 Copy Number Is Increased in Some Cancer Cell Lines
To identify a mechanism that might contribute to Cdc7 and Dbf4
overexpression, we examined CDC7 and DBF4 gene copy num-
ber. DBF4 is located at 7q21.12 and CDC7 at 1p22.2. We per-
formed DBF4 FISH on the breast, ovarian, and prostate cancer cell
lines (Figure 2 and Table 2). As a control, we performed FISH on
phytohemagglutinin-stimulated lymphocytes derived from a karyo-
typically normal male donor (Figure 2A). Fluorescence in situ hybrid-
ization patterns observed in the interphase and metaphase spreads
of the cancer cell lines OVCAR-8 and OVCAR-4 suggest that gene
dosage is one of themechanisms by whichDbf4 protein level is altered.
For these two ovary cancer cell lines, we can easily visualize the pres-
ence of two and four extra copies of the DBF4 gene for OVCAR-8
and OVCAR-4, respectively (Figure 2, B and C ).
Fluorescence in situ hybridization analyses on interphase nuclei
were used to quantify the number of DBF4 gene copies per CEP7
copies per cell in the cell lines. A ratio ≥ 1.5 for DBF4 (orange) to
CEP7 (green) was observed in three (OVCAR-3, OVCAR-4, and
OVCAR-8) of six ovary cell lines (Table 2). These results are consis-
tent with increased Dbf4 protein levels in these three cell lines (Fig-
ure 1I ). We also found a DBF4/CEP7 ratio of 0.64 for OVCAR-5,
which correlated with our inability to detect Dbf4 protein in this
cell line (Table 2 and Figure 1I ). We also examined relative DBF4
copy number in the two prostate cancer cell lines, namely, DU-
145 and PC-3. Although the calculated ratios were 1 for both cell
lines (Table 2), we observed more DBF4 gene copies, that is, four
for DU-145 and six for PC-3, due to increased copies of chromo-
some 7 (Table 2). Among the breast cancer cell lines, NCI/ADR-
RES and MCF7 showed an increased DBF4/CEP7 ratio (Table 2).
For the NCI/ADR-RES, we obtained a ratio of 2, consistent with
the ratio calculated for the OVCAR-8 cell line, from which NCI/
ADR-RES is derived [41]. For the MCF7 cells, we calculated a ratio
Table 1. Doubling Time, Ploidy, Cdc7 Expression Level, and TP53 Gene Status in the 57 Cell
Lines from the NCI-60 Set.
Panel Name Cell Name Doubling Time* Ploidy† Cdc7 Band
Intensity‡
TP53 Gene
Status
Central nervous
system cancer
SNB-19§ 34.6 3 ++++ m
SNB-75 62.8 2 ++ m
U251§ 23.8 2 ++ m
SF-268 33.1 2 + m
SF-295 29.5 5 +++ m
SF-539 35.4 4 + m
Colon cancer HT29 19.5 3 ++ m
HCC-2998 31.5 2 − m
HCT-116 17.4 2 ++++ wt
SW-620 20.4 2 ++++ m
COLO 205 23.8 3 + m
HCT-15 20.6 2 ++++ m
KM12 23.7 2 ++++ m
Non–small cell
lung cancer
NCI-H23 33.4 2 ++++ m
NCI-H226 61 3 − wt
NCI-H322M 35.3 2 − m
NCI-H460 17.8 2 + wt
NCI-H522 38.2 2 +++ m
A549/ATCC 22.9 3 − wt
HOP-62 39 4 + m
HOP-92 79.5 4 +++ m
EKVX 43.6 3 − m
Leukemia RPMI-8226 33.5 3 − m
K-562 19.6 3 ++++ m
CCRF-CEM 26.7 2 + m
HL-60(TB) 28.6 2 − m
MOLT-4 27.9 4 ++ m
SR 28.7 2 − wt
Melanoma MALME-3M 46.2 4 − wt
SK-MEL-2 45.5 4 ++ m
SK-MEL-5 25.2 4 − wt
SK-MEL-28 35.1 4 − m
UACC-62 31.3 3 − wt
UACC-257 38.5 3 ++ wt
M14¶ 26.3 3 ++ m
MDA-MB-435¶ 25.8 2 +++ m
Kidney cancer UO-31 41.7 2 +++ wt
SN12C 29.5 3 ++++ m
A498 66.8 3 ++ wt
CAKI-1 39 3 − wt
ACHN 27.5 2 ++ wt
786-0 22.4 4 ++++ m
TK-10 51.3 4 ++++ m
Ovary cancer OVCAR-3 34.7 3 ++ m
OVCAR-4 41.4 3 + m
OVCAR-5 48.8 2 − wt
OVCAR-8¶ 26.1 2 ++++ m
IGROV1 31 4 ++ m
SK-OV-3 48.7 4 − m
Prostate cancer DU-145 32.3 3 ++++ m
PC-3 27.1 4 ++++ m
Breast cancer T-47D 45.5 2 − m
MCF7 25.4 3 − wt
NCI/ADR-RES$ 34 2 ++ m
BT-549 53.9 3 ++ m
HS 578T 53.8 3 + m
MDA-MB-231/
ATCC
41.9 2 ++ m
*Doubling time in hours (see http://dtp.nci.nih.gov/docs/misc/common_files/cell_list.html).
†For the ploidy, 2 means diploid, numbers greater than 2 indicate an increase of the chromosome
number.
‡Cdc7 protein expression level was scored from the immunoblot analysis presented in Figure 1 as
follows: “−” indicates no Cdc7 expression; “+,” low Cdc7 expression; “≥++,” Cdc7 overexpression.
§Indicate cell lines that were shown to be derived from the same tumor.
¶Indicate cell lines that were shown to be derived from the same tumor.
$Indicate cell lines that were shown to be derived from the same tumor.
m, indicates mutant; wt, wild type.
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of 2.57; however, this cell line did not have increased Dbf4 protein
levels (Figure 1K ). The lower ratio obtained for the T-47D (0.54)
once again correlated with the absence of detectable Dbf4 protein
(Figure 1K ).
We also examined CDC7 copy number using FISH (Spectrum
Orange-labeled) for the six breast cancer cell lines relative to a control
probe on the 1q arm (SpectrumGreen-labeled) but found no evidence
of CDC7 gene amplification on interphase nuclei (data not shown).
Cdc7 Protein Is Highly Expressed in Some Primary Tumors
We examined 20 breast carcinomas, 10 colorectal cancers, and 5
non–small lung cancers from 35 different patients by immunohisto-
chemical staining, using a combination of two monoclonal antibodies
against Cdc7 protein. As expected, the Cdc7 staining in each case
was nuclear as determined by the hematoxylin counterstaining of
the nuclear structures. In each case, the negative controls with either
no primary or secondary antibody showed no staining (data not
shown). Cdc7 protein was scored as (−) when absent, (+) when the
staining was weak, and (≥++) when the staining was intense. We were
able to detect weak Cdc7 protein in 5 of 20 breast carcinomas and
intense staining in 15 of 20 tumors (Table W2). Interestingly, 6 of
15 breast tumors overexpressing Cdc7 protein were metastatic but
0 of 5 tumors that exhibited weak staining were metastatic. We ob-
tained the same trend for the colon cancers: all stained for Cdc7 pro-
tein, 2 of 10 had low levels and 8 of 10 were intensely stained for
Cdc7 protein (Table W2). For the lung cancers, three of five sections
showed no Cdc7 staining but two of five revealed Cdc7 overexpres-
sion (Table W2). In summary, 71% (25/35) of the primary tumors
we tested had significantly elevated Cdc7 protein levels.
For six patient samples, we performed the immunohistochemistry
on tumor sections and matched normal tissues. We observed Cdc7
nuclear staining for primary tumors but no staining in the adjacent
normal tissues in all six patients. Representative pictures are shown
for normal breast tissue and breast carcinoma (Figure 3A) and for
normal colon tissue and colon carcinoma (Figure 3B). These results
correlate very well with the immunoblot analysis results described
previously, which detected Cdc7 expression in some cancer cell lines
but not in normal cells or tissues.
DBF4 Gene Status in Human Primary Tumors
Overexpressing Cdc7 Protein
To determine if increased copies of the DBF4 or CDC7 genes oc-
curred in primary tumors, we performed DBF4 and CDC7 FISH on
seven breast and three colon primary tumors with high Cdc7 protein
expression. Interestingly, we found one breast carcinoma that had in-
creased DBF4 copy number with ∼10 copies of the DBF4 gene and
5 copies of the CEP7 control (counting data not shown; Figure 3C ).
We saw no evidence for CDC7 duplication or amplification. Consis-
tent with the results seen in the cancer cell lines, increased DBF4
gene copy number may also occur in some primary tumors.
CDC7 and DBF4 mRNA Expression Is Increased in Multiple
Primary Tumors of Diverse Origin
Finally, we examined CDC7 and DBF4 gene expression in 678
tumors of diverse origin relative to the expression in the normal tis-
sues. These data were obtained from the Gene Expression Omnibus
(GSE2109). Unprocessed gene expression data derived from more
Figure 2. Increased DBF4 copy number in cancer cell lines. Fluores-
cence in situhybridization experimentsweredonewith a centromeric
probe specific to the chromosome7 (CEP7; SpectrumGreen-labeled)
versus the DBF4-specific probe (SpectrumOrange-labeled) on inter-
phase nuclei and on metaphase spreads. (A) Control FISH experi-
ment was done on phytohemagglutinin-stimulated lymphocytes
derived from a karyotypically normal male donor. Pictures are also
shown for two ovary cancer cell lines OVCAR-8 and OVCAR-4 (B
and C), respectively.
Table 2. DBF4 Gene Dosage in Ovary, Prostate, and Breast Cancer Cell Lines.
Cancer Cell Lines DBF4 DBF4/CEP7 Ratio
Range Mean
Ovary
OVCAR-3 2–13 3.78 1.55
OVCAR-4 4–13 6.46 1.55
OVCAR-5 1–3 2.06 0.64
OVCAR-8* 3–9 4.28 1.95
IGROV1 3–9 4.04 1.24
SK-OV-3 2–3 2.46 1.02
Prostate
DU-145 3–6 3.62 1.02
PC-3 5–14 6.16 1
Breast
T-47D 2–4 2.28 0.54
MCF7 4–6 5.4 2.57
NCI/ADR-RES* 3–5 4.18 2.07
BT-549 1–6 2.98 0.97
HS 578T 1–6 2.72 0.97
MDA-MB-231/ATCC 2–6 2.78 1.00
Range denotes the range of signals per cell counted in 50 nuclei for each cell line, and mean
denotes the mean number of signals per cell. Gene overrepresentation is noted if the ratio of
DBF4/CEP7 is ≥1.5 and gene amplification is noted if the ratio is ≥2.5.
*Indicates cell lines that were shown to be derived from the same tumor.
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 Figure 3. Immunostaining of Cdc7 in primary breast and colon tumors. (A) Cdc7 protein staining of normal breast tissue (left) and the
corresponding breast carcinoma (right) shown at low and high (below) magnifications. (B) Normal colon tissue (left) and tumor (right)
stained for Cdc7 protein at low and high (below) magnifications. (C) Fluorescence in situ hybridization experiments were done as described
in Figure 2. A representative picture of nuclei from a breast primary tumor showing increased DBF4 gene copy number is shown.
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than 1000 tumors were preprocessed using the RMA method as de-
scribed in the Materials and Methods section. For each tumor gene
expression value, the median gene expression value of the cor-
responding normal tissue was subtracted, which was possible for
678 tumor samples. As shown in Figure 4A, both CDC7 and
DBF4 expressions were significantly increased relative to normal con-
trols in most of the 12 tumor types in this data set. DBF4 expres-
sion was consistently high in tumors of the colon, lung, and ovary,
whereas CDC7 was consistently high in tumors of the breast and
lung. When we examined the expression of both genes in individual
tumor samples, we found a significant correlation (P ≤ 2.2 × 10−16)
for their coordinate expression (Figure 4B). These data agree well
with our survey of Cdc7 and Dbf4 protein expression in cancer cell
lines and primary tumors and argue that high CDC7 and DBF4 ex-
pression is a common occurrence in human tumors.
siRNA-Mediated Knockdown of CDC7 Causes Growth Arrest
and Apoptosis in Tumor Cell Lines
Cdc7 has been shown to be essential in mammalian cells by anti-
body microinjection experiments [10], a targeted knockout of the mu-
rine CDC7 gene [45], and siRNA against CDC7 expression in human
cells [33]. We independently found that siRNA-mediated knockdown
Figure 4. Overexpression of CDC7 and DBF4 in human cancers. (A) The gene expression level of CDC7 and DBF4 in tumor samples
compared with corresponding normal tissue (see the Materials and Methods section). Plotted is the fold increase or fold decrease in
gene expression in each tumor sample (n = 678). Red bars highlight the tumors that have increased gene expression. (B) CDC7 and
DBF4 expression data described in (A) as a scatter plot with correlation coefficient, significance value (boxed), and best-fit line generated
using linear regression.
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of Cdc7 in HeLa cells caused growth arrest followed by apoptosis (Fig-
ure 5 and Figure W2) but that Cdc7 knockdown in the normal im-
mortalized fibroblast cell line WI-38 caused growth arrest with high
viability but with no apoptotic induction (not shown). As a control,
non–target siRNA-transfected HeLa cells behaved similarly to the
mock-transfected cells in that they retained Cdc7 protein expression
and did not significantly undergo an apoptotic response (Figure W2).
We show blots for Cdc7 protein at 48 and 72 hours after transfection
(Figure 5A), but we typically see that Cdc7 protein is undetectable at
24 hours after transfection and remains absent through the 96-hour
time point (Figure W2). We further examined the result of CDC7
knockdown in the two prostate cell lines of the NCI-60 panel, namely,
DU-145 and PC-3 cells. Both of these cell lines express high levels
of Cdc7 and Dbf4 protein (Figure 1J ). Cdc7 knockdown in these
two cells also causes growth arrest but only a small fraction of cells
undergo apoptosis, evidenced by the TUNEL assay (Figure 5, B and
C ) and PARP blots (Figure 5D). Both cell lines maintain a high
viability by Trypan blue staining after Cdc7 knockdown (data not
shown). Because both of these cell lines are mutant for p53 and are
capable of undergoing apoptosis under various conditions [46,47],
the large difference in apoptotic response with HeLa cells suggests
some other underlying genetic difference. PC-3 cells are known to
express high levels of the antiapoptotic regulator Bcl-2 [46,47], so this
might contribute to their failure to undergo significant apoptosis after
Cdc7 knockdown.
Discussion
Cdc7 and Dbf4 proteins form a complex in vivo [3] to generate an
active protein kinase in all organisms tested (reviewed by Sclafani
[2]). Human Cdc7-Dbf4 kinase activity is essential for cell prolifer-
ation by activating DNA replication [10,32,33] (and data not
shown). Although Cdc7 abundance is constant through the cell cy-
cle, its kinase activity is strictly dependent on Dbf4, which signifi-
cantly increases in abundance before S-phase entry.
The NCI-60 cell lines represent the most common forms of cancer
in the United States [48] and are widely used by the research com-
munity. Unfortunately, neither CDC7 nor either of the DBF4-related
Figure 5. siRNA knockdown of CDC7 in tumor cell lines causes growth arrest and apoptosis. (A) Cdc7 immunoblots at 48 and 72 hours
after transfection for mock and Cdc7 siRNA-transfected HeLa, DU-145, and PC-3 cells. Actin loading control is shown below. (B) Graphs
showing cell number for control-transfected (♦) and Cdc7 knockdown cells (▪) over time. Data represent the mean of at least two ex-
periments ± SD. (C) The percentage of TUNEL-positive cells are shown for each cell line for control transfected (light gray bars) and
Cdc7 knockdown cells (dark gray bars) +/− SD. (D) Immunoblots of PARP full length (FL) and cleavage product (CL) are shown for the
transfection time course.
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genes were represented in the published microarray data for the NCI-
60 cell lines [49–51]. In this study, we showed that there was a wide
range of Cdc7 protein expression among the NCI-60 cell lines and
five additional leukemia cell lines. In contrast, we consistently ob-
served low or undetectable Cdc7 protein in normal tissues and cell
lines. Our results support and significantly extend a previous exam-
ination of CDC7 mRNA expression in cell lines and different primary
tumors versus normal tissues [29]. Hess et al. [29] found a significant
number (15/48) of the tumor samples expressing CDC7 mRNA at
higher levels than those seen in the normal tissue. We determined that
∼50% of tumor cell lines we tested expressed high levels of Cdc7 and
Dbf4 protein, including many leukemia cell lines. These data suggest
that Cdc7-Dbf4 protein has a relatively low abundance in normal cells
and is perhaps absent in nonproliferating tissues but has increased ex-
pression in some cancer cell lines derived from diverse tissues.
We also defined a significant correlation between Cdc7 protein ex-
pression level and the TP53 gene status. On the basis of published
mutational data in tumor suppressor or oncogenes in the NCI-60 cell
line set [43], we established that Cdc7 overexpression is frequently as-
sociated with the presence of mutation(s) in the TP53 gene. We also
found that CDC7 and DBF4 expression levels were highly correlated
with TP53 status in primary breast tumors, suggesting either that p53
directly represses the CDC7 and DBF4 genes [44] or its loss indirectly
activates CDC7 and DBF4 expression. However, we saw no difference
in CDC7 and DBF4 expression in isogenic HCT-116 cell lines that
differ only by deletion of TP53. Also, induction of p53 in HCT-
116 cells after exposure to bleomycin did not alter CDC7 or DBF4
mRNA expression. Because we also found some p53 mutant cell lines
that had barely detectable Cdc7-Dbf4 protein expression, together
these data indicate that p53 inactivation alone does not determine
whether the protein kinase is highly expressed. It may be that p53 loss
and an additional genetic alteration that frequently occurs during tu-
morigenesis give rise to increased Cdc7-Dbf4 expression.
Because Cdc7-Dbf4 is a two-subunit kinase, it was of interest to in-
vestigate whether Cdc7 and Dbf4 protein expressions were correlated in
primary tumors and cancer cell lines. We analyzed the Dbf4 expression
in 62 cancer cell lines with varying Cdc7 expression levels and found a
tight correlation between the expression levels of both proteins. Dbf4
protein is frequently coexpressed with Cdc7 and low levels of Dbf4
correspond with low or undetectable levels of Cdc7 protein. Therefore,
in the cancer cell lines we analyzed, the expression of the two partners is
highly correlated. Expression of the two genes was also highly correlated
in 678 tumors of diverse origin (P ≤ 2.2 × 10−16).
A comparative genomic hybridization analysis of 38 breast cancer
cell lines showed that the 7q21–22 region, containing the DBF4 gene,
is an amplification site (11% of the cases) [52]. Moreover, the regional
gene activation of this region was also found as a potential mechanism
for acquired drug resistance, with or without changes in gene dosage
and in breast and ovary cancer cell lines [53,54]. We naturally won-
dered if gene amplification could explain the higher Dbf4 protein ex-
pression seen in a subset of tumor cell lines. Seven of 14 ovarian,
breast, and prostate tumor cell lines had an increased copy number
of the DBF4 gene (by FISH analysis) resulting from unbalanced chro-
mosome translocations or increased chromosome 7 copy numbers.
With the exception of MCF7, these cell lines also had increased
Dbf4 protein levels. In contrast, FISH analysis revealed no evidence
for increased CDC7 copy number, indicating that the increased
Cdc7 protein expression was independent of 1p22 amplification in
the cell lines we examined. Other mechanisms, such as epigenetic
modification and chromatin remodeling, may contribute to the re-
gional gene activation in this region. Recently, a group identified that
melanoma cell lines with defects in the DNA damage G1 checkpoint
displayed an enhanced expression of proliferation-associated genes
such as CDC7 [55].
The results obtained by immunohistochemistry on primary tumors
paralleled our immunoblot analyses on cell lines. We showed that
Cdc7 protein could be detected directly in primary tumors but not
in the normal tissues. Of 35 tumors from breast, colon, and lung,
25 exhibited high-level Cdc7 expression. Of particular interest was
the finding that 15 of 20 breast carcinomas showed intense Cdc7
staining suggesting that increased Cdc7 expression may be a common
feature of breast cancer. Because six metastatic breast carcinomas
showed intense Cdc7 staining, increased Cdc7 expression occurs in
more aggressive tumors as well. We further showed that most breast
cancers surveyed increased CDC7 expression over normal controls
(162/181 ≥ 1.5-fold and 123/181 ≥ 2-fold increase; Figure 4A).
We found that DBF4 expression was increased in almost all 678
tumors we surveyed, especially tumors of the colon, lung, and ovary.
Recently, it was shown that Dbf4 protein was not only associated
with a higher relative change in the transition from nevi to cutaneous
melanoma but was also up-regulated in a high number of primary
melanoma and melanoma metastasis patients [32]. On the basis of
our data, it is possible that increased DBF4 copy number or p53 loss
might contribute to Dbf4 protein overexpression. The Cdc6 and
Mcm5 replication initiation proteins are also overexpressed in cervi-
cal and bladder carcinomas [26,28] suggesting that increased expres-
sion of particular replication initiation proteins may be a common
feature of certain tumors. Taken together, these data suggest that in-
creased Cdc7 and Dbf4 expression may be selected during tumori-
genesis in some tissue types.
It will be of interest to determine the functional consequences of
altered Cdc7 and Dbf4 protein expression levels across multiple cell
lines. Previous studies have shown that knockdown of Cdc7 in the
HeLa cervical cancer cell line (but not normal cells) results in an
apoptotic response [33]. We saw the same effect but note that in
two prostate cancer cell lines, loss of Cdc7 did not result in significant
apoptosis. Because Cdc7-Dbf4 is required for entry into S-phase,
higher levels of Cdc7-Dbf4 kinase might aid the proliferative capac-
ity of tumor cells. However, increased Cdc7 expression was not cor-
related with the proliferative status of the cells (P = .271). Therefore,
increased Cdc7 expression is apparently not required for a high pro-
liferation rate. In fact, transient overexpression of the hamster Cdc7
and/or Dbf4 caused a cell cycle arrest [56], and in human cells, over-
expression of both human Cdc7 and Dbf4 does not cause significant
effects on cell cycle progression [57]. Because Cdc7-Dbf4 has been
implicated in the response to stalled forks or various forms of DNA
damage [7,17–20], increased Cdc7-Dbf4 kinase may instead aid re-
covery or repair of stalled replication forks to enhance survival of
some tumor cells. Together, these observations suggest that increased
Cdc7-Dbf4 expression may be a common and/or important step dur-
ing tumorigenesis.
Supplemental Materials and Methods
Bleomycin Treatment
Bleomycin Sigma-Aldrich was resuspended in water at 20 mg/ml.
A final concentration of 5 μg/ml was added the culture medium for
2 and 4 hours.
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Reverse Transcription–Polymerase Chain Reaction
Total RNA was extracted from the cells using Trizol (Invitrogen)
according to the manufacturer’s instructions. Approximately 0.5 μg
of total DNase-treated RNA from each cell line was reverse-transcribed
to cDNA and amplified using SuperScript One-Step RT-PCR with
Platinum Taq (Invitrogen) in a final volume of 50 μl. The cDNA
synthesis was done at 52°C for 30 minutes then the cDNA was
amplified following different conditions depending on the mRNA,
in duplicate. The following oligonucleotide primer sets were used
for the reactions with expected product size in parentheses: CDC7
(681 bp) 5′-GGCAAGATAATGTCATGGGA-3′ (sense) and 5′-
TCCTCATCACAGCACTATTC-3′ (antisense); DBF4 (515 bp)
5′-GCATATACTGCAGAAACCACT-3′ (sense) and 5′-GAG-
GTTCCACCATACTTATC-3′ (antisense); β-actin (353 bp) 5′-
GCTCGTCGTCGACAACGGCTC-3′ (sense) and 5′-CAAACA-
TGATCTGGGTCATCTTCTC-3′ (antisense). The primers were
designed to span adjacent exons to avoid genomic DNA contami-
nation. Polymerase chain reactions were carried out for 2 minutes at
94°C followed by 27 (for β-actin), 28 (for CDC7), and 33 cycles (for
DBF4) of 15 seconds at 94°C, 30 seconds at 52°C, and 1 minute at
68°C, followed by a 5-minute extension at 68°C. The products were
separated by electrophoresis on 1.2% agarose gels in 1× TAE (Tris–
acetate–EDTA) buffer and were detected by ethidium bromide stain-
ing. The β-actinmRNAwas used as a control for equal sample loading.
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Table W1. Cdc7 Expression Level and TP53 Gene Status in the 57 Cell Lines from the NCI-60
Set (Independent Measurements).
Panel Name Cell Name Cdc7 Band
Intensity*
TP53 Gene
Status
Central nervous
system cancer
SNB-19† − m
SNB-75 ++ m
U251† − m
SF-268 + m
SF-295 ++ m
SF-539 + m
Colon cancer HT29 − m
HCC-2998 + m
HCT-116 ++ wt
SW-620 ++ m
COLO 205 + m
HCT-15 +++ m
KM12 ++++ m
Non–small cell
lung cancer
NCI-H23 +++ m
NCI-H226 − wt
NCI-H322M + m
NCI-H460 − wt
NCI-H522 +++ m
A549/ATCC − wt
HOP-62 − m
HOP-92 ++++ m
EKVX − m
Leukemia RPMI-8226 + m
K-562 +++ m
CCRF-CEM ++ m
HL-60(TB) − m
MOLT-4 ++++ m
SR + wt
Melanoma MALME-3M + wt
SK-MEL-2 ++ m
SK-MEL-5 + wt
SK-MEL-28 − m
UACC-62 − wt
UACC-257 − wt
M14‡ − m
MDA-MB-435‡ ++ m
Kidney cancer UO-31 − wt
SN12C ++ m
A498 − wt
CAKI-1 − wt
ACHN + wt
786-0 + m
TK-10 + m
Ovary cancer OVCAR-3 +++ m
OVCAR-4 ++ m
OVCAR-5 − wt
OVCAR-8§ ++++ m
IGROV1 ++ m
SK-OV-3 + m
Prostate cancer DU-145 ++++ m
PC-3 ++++ m
Breast cancer T-47D − m
MCF7 + wt
NCI/ADR-RES§ ++ m
BT-549 − m
HS 578T − m
MDA-MB-231/ATCC + m
*Cdc7 protein expression level was scored from the second set of measurements as follows: “−”
indicates no Cdc7 expression; “+,” low Cdc7 expression; “≥++,” Cdc7 overexpression.
†Indicate cell lines that were shown to be derived from the same tumor.
‡Indicate cell lines that were shown to be derived from the same tumor.
§Indicate cell lines that were shown to be derived from the same tumor.
m, indicates mutant; wt, wild type.
Figure W1. CDC7 and DBF4 mRNA levels after p53 induction. (A) Comparison of the CDC7 and DBF4 mRNA levels in two HCT-116 cell
lines with a different TP53 status (−/− or +/+). CDC7, DBF4, and β -actin mRNA were reverse-transcribed and amplified as described in
the Supplementary Materials and Methods section. p53 immunoblot is also shown for each cell line. (B) Comparison of the CDC7 and
DBF4 mRNA levels in HCT-116 p53+/+ cells after exposure to bleomycin (5 μg/ml) at 0, 2, and 4 hours of treatment. p53 immunoblot is
shown to confirm its induction after bleomycin treatment.
Table W2. Cdc7 Immunohistochemical Staining for Breast, Colon, and Lung Primary Tumors.
Tumor Origins Sample Numbers No Cdc7 Detection (−) Low Cdc7 Detection (+) Cdc7 Overexpression (≥++)
Breast 20 0 5 15
Colon 10 0 2 8
Lung 5 3 0 2
Total 35 (100%) 3 (9%) 7 (20%) 25 (71%)
Cdc7 protein expression level was scored from the immunohistochemical staining as follows: “−” indicates no Cdc7 staining (= no Cdc7 expression); “+,” low Cdc7 staining (= low Cdc7 expression); “≥++,”
intense Cdc7 staining (= Cdc7 overexpression).
Figure W2. Comparison of mock, nontarget siRNA, and Cdc7 siRNA transfections on cell growth and apoptosis induction in HeLa cells.
(A) Cdc7 immunoblots following the different transfections at 0, 24, 48, 72, and 96 hours after transfection. Ten micrograms of total
protein was separated on 10% SDS-PAGE. Equal loading was confirmed by probing with a β-actin–specific antibody. (B) Graph of the
cell growth after transfection at 0, 24, 48, 72, and 96 hours (M indicates mock; NT, nontarget siRNA; Cdc7, Cdc7 siRNA). (C) Percentage
of TUNEL-positive cells for the mock (light gray bars), the nontarget siRNA (striped bars), and the Cdc7 siRNA (dark gray bars) trans-
fected cells at 0, 24, 48, 72, and 96 hours after transfection.
